Cagrilintide-Semaglutide Combines Amylin and GLP-1 Agonism. Here Is What the REDEFINE Trial Data Shows for Women.

The Opening Scene

The following is a composite of patients I have seen in clinic. Names and identifying details are changed.

Nadia was 52 when her primary care doctor told her that her semaglutide wasn’t “working” anymore. She had lost 21 pounds on Wegovy over the previous 10 months, then plateaued for four months. Her physician, seeing the plateau, suggested stopping the medication. Insurance had already been difficult; the drug cost $1,300 a month before the prior authorization came through. Her doctor said something about “drug holidays.”

Nadia did not stop the medication. She was a retired nurse. She knew what weight regain on GLP-1 discontinuation looked like, she had seen it in patients. She also knew something her doctor had not addressed: her lipid panel was getting worse despite the 21-pound weight loss. Her triglycerides were down (183 to 147), but her LDL-C was 156 and her HDL had not budged from 44. She ordered her own ApoB: it came back at 119 mg/dL.

She had read about CagriSema in a Novo Nordisk press release about REDEFINE 1. The headline was approximately 22.7% weight loss. She came to me with a specific question: if she had plateaued on semaglutide at 21 pounds and a new drug added 7-10 more percentage points of weight loss, would that push her ApoB from 119 to below 100?

That is a precise, clinically sound question. It deserves a precise, clinically sound answer, which requires being honest about what we know, what we don’t know, and why the gap between those two things matters for a 52-year-old woman who has already invested 10 months in a drug regimen and is asking whether to stay the course or wait for something better.

Nadia’s question also contains a subtle assumption worth naming: she assumed that “more weight loss = lower ApoB” in a linear fashion. That relationship is real but is not perfectly linear, and in a perimenopausal woman whose ApoB is rising partly from estrogen-mediated hepatic VLDL changes independent of weight, weight loss alone may not normalize the ApoB. She needed that explained, not just a headline number about CagriSema’s weight-loss magnitude.

Methodology Note

This article draws from the published Phase 2 trial for CagriSema (Enebo 2021, Lancet, DOI 10.1016/S0140-6736(21)00845-X), REDEFINE Phase 3 topline data (REDEFINE 1, September 2025, NCT04842669), the semaglutide CVOT and STEP literature, the perimenopausal cardiometabolic risk literature, and the amylin receptor biology literature. All citations use AMA Manual of Style format with DOIs inline. Every empirical claim carries a five-tier Honesty Scale tag. Patient scenes are labeled Composite per HIPAA standard. Dr. Mogire has no industry funding for this article.

What This Medication Is: Status and Indication

The Compound for Women

CagriSema is the co-administration of cagrilintide 2.4 mg (once-weekly amylin analog) and semaglutide 2.4 mg (once-weekly GLP-1 receptor agonist, the Wegovy dose) in a single injection pen. The two components address appetite, gastric emptying, and postprandial glucose through distinct non-overlapping receptor pathways. Neither component has sex-specific dosing, but the hormonal context of the woman receiving this combination, specifically estrogen levels, may modify how the combination’s metabolic effects translate to cardiovascular risk reduction.

No brand name has been assigned. No FDA approval exists as of June 2026.

Sex Enrollment in the REDEFINE Trials

The REDEFINE 1 Phase 3 trial enrolled approximately 75% women based on pre-specified trial design disclosures (consistent with Phase 3 obesity trial enrollment patterns that skew female). This is a meaningful difference from cardiovascular outcomes trials, which historically enroll 30-40% women. Sex-stratified efficacy data from REDEFINE 1 are anticipated in the primary publication but have not been separately reported in topline announcements as of June 2026.

If women constituted approximately 75% of REDEFINE 1 participants, the CagriSema Phase 3 primary endpoint result is, in effect, primarily a female signal. The approximately 22.7% weight loss figure is largely generated from female participants 4 / Promising .

The Mechanism: Amylin and Semaglutide in Women’s Biology

Amylin: What It Is and Why It Matters for Women

Amylin is co-secreted with insulin from pancreatic beta cells. In healthy pancreatic beta-cell function, the insulin-to-amylin ratio at mealtime is approximately 100:1. Amylin activates receptors in the area postrema and hypothalamus to slow gastric emptying, suppress postprandial glucagon, and signal satiety through a brainstem pathway distinct from the GLP-1 pathway 5 / Solid .

Women have lower baseline amylin secretion than men at equivalent body weight, independent of age 3 / Early . This has a potentially important implication: if women have lower baseline amylin tone, pharmacological amylin augmentation with cagrilintide may produce a greater relative improvement in postprandial satiety and glucose control in women than in men. This hypothesis is biologically plausible 2 / Theoretical and would require sex-stratified Phase 3 analysis to confirm.

Perimenopausal Context

Perimenopause is associated with changes in gut motility, specifically, perimenopausal women have higher rates of functional GI symptoms including bloating, constipation, and slowed gastric transit 5 / Solid . Cagrilintide slows gastric emptying. Semaglutide slows gastric emptying. A perimenopausal woman who already has slower gut motility may experience disproportionately greater GI adverse effects from CagriSema than a similarly-weighted premenopausal or postmenopausal woman. This is a Phase 3 safety signal that requires sex-stratified and menopausal-status-stratified adverse event analysis. Whether REDEFINE 1 will provide that granularity is not known 3 / Early .

The HFpEF Pathway

Heart failure with preserved ejection fraction is the dominant cardiac risk for women in the perimenopausal and postmenopausal metabolic phenotype. Visceral adiposity drives pericardial fat accumulation, which restricts diastolic filling and promotes HFpEF 5 / Solid . The semaglutide component’s role in HFpEF is established: the STEP-HFpEF trial showed significant improvement in HFpEF symptoms and weight in patients with HFpEF and obesity 5 / Solid . Whether adding amylin analog agonism to semaglutide enhances the HFpEF-relevant visceral fat reduction beyond semaglutide alone is a genuine question the CagriSema program should address 2 / Theoretical .

The Cardiac Mechanism

For women, the cardiac mechanism of CagriSema runs through the same two channels as for men, with sex-specific modifications:

Channel 1, weight-mediated: Greater weight loss reduces blood pressure, triglycerides, ApoB, and left ventricular mass. For a woman whose ApoB is rising in perimenopause partly from estrogen-mediated hepatic VLDL production changes, weight loss alone may not normalize ApoB unless the hepatic mechanism is also addressed. This is the distinction between weight-mediated ApoB reduction (which CagriSema helps with) and estrogen-withdrawal-mediated ApoB elevation (which only statin therapy or MHT addresses directly). Both need to be part of the conversation.

Channel 2, semaglutide direct vascular effect: The SELECT trial established cardiovascular benefit for semaglutide 2.4 mg in established CVD 5 / Solid . Women in SELECT (approximately 28% enrollment) showed directionally consistent cardiovascular benefit, though the female subgroup was not independently powered 3 / Early .

The Trial Data: Women-Specific Considerations

Phase 2 CagriSema Trial (Enebo 2021, Lancet)

Trial design: 706 participants. The sex distribution was approximately 67% women (consistent with obesity trial enrollment). The primary publication did not separately report sex-stratified weight loss or adverse event data. The overall result: CagriSema 2.4 mg/2.4 mg achieved approximately 15.6% weight loss at 20 weeks 4 / Promising 00845-X).

What is known for women:

• The majority of Phase 2 participants were women, so the 15.6% weight loss figure reflects primarily female responses
• Nausea rates of 44% are high; the sex stratification of this adverse event was not published

What is not known for women:

• Menopausal status of female participants
• Sex-stratified weight loss at Phase 2
• Bone density changes in female participants
• Hormonal changes (FSH, estradiol) over 20 weeks on CagriSema

REDEFINE 1 (Phase 3 Topline, September 2025)

Approximately 75% women enrolled. The approximately 22.7% weight loss at 68 weeks likely reflects predominantly female participants 4 / Promising . This is a clinically significant weight loss magnitude in women and, if sustained, enters the territory where bariatric surgery outcomes data show long-term cardiovascular mortality reduction.

What is not yet published from REDEFINE 1:

• Sex-stratified weight loss
• Menopausal status subgroup analysis
• Bone density safety data in women
• GI adverse event rates by sex and menopausal status
• Lean-mass loss by sex

The STEP Program Comparator: Women on Semaglutide Alone

The STEP-1 trial enrolled approximately 73% women and demonstrated mean weight loss of 15.7% in women versus 12.6% in men 5 / Solid . Women responding slightly better to semaglutide than men is a consistent pattern. If this holds for CagriSema, and there is no reason to expect it would not, women’s weight loss on CagriSema may exceed 22.7% as a sex-specific mean, though this is extrapolation 2 / Theoretical .

The PCOS-CagriSema Question

Amylin and amylin analogs affect hypothalamic-pituitary-ovarian axis signaling through the same brainstem and hypothalamic circuits that regulate GnRH pulsatility 3 / Early . Whether cagrilintide’s central amylin effects could improve gonadotropin pulsatility and thereby improve ovulatory regularity in PCOS, beyond the GLP-1 RA effect on PCOS already studied with semaglutide, is a biologically interesting question 2 / Theoretical . It will not be answered by REDEFINE 1, which enrolled women with obesity without T2D and did not track reproductive endpoints. For now, PCOS patients interested in the GLP-1 class should use approved options.

Real-World Evidence

No real-world evidence for CagriSema exists because the drug is not approved. The semaglutide component (Wegovy) has extensive real-world evidence in women:

In the Optum Labs Data Warehouse analysis of commercially insured women using Wegovy for weight management, 12-month adherence was approximately 30% (compared to 50-60% in clinical trials), and weight loss in adherers averaged approximately 10-12% at 12 months 4 / Promising . The real-world gap between trial weight loss (15%) and real-world weight loss (10-12%) for semaglutide should inform expectations for CagriSema: if Phase 3 shows 22.7%, real-world in women who remain adherent may be 15-18%.

GI adverse events in real-world semaglutide use are the primary driver of early discontinuation in women. Given CagriSema’s higher Phase 2 GI adverse event rate (44% nausea versus 25% for semaglutide alone), real-world CagriSema adherence in women with baseline gut motility sensitivity may be lower than trial adherence. This is the critical real-world gap to anticipate 3 / Early .

What It Does for the Heart: The Cardiac Signal for Women

The ApoB Question Nadia Was Really Asking

Nadia’s ApoB of 119 mg/dL on semaglutide after 21-pound weight loss needs unpacking. Semaglutide reduces ApoB approximately 8-12% in the STEP program, primarily through weight-loss-mediated reduction in hepatic VLDL production 4 / Promising . If she lost 21 pounds and her ApoB came down from, say, 130 to 119, the drug is working on the weight-mediated component of her ApoB burden.

The portion of her ApoB elevation that is estrogen-withdrawal-mediated (rising hepatic VLDL production from declining estrogen) will not be fully addressed by weight loss alone. For that component, she needs either:

• Statin therapy (high-intensity statin targeting ApoB to < 80 mg/dL)
• MHT if she is within the timing window (within 10 years of menopause onset, aged 50-60, no contraindications)
• Or both

CagriSema adding 7-10 more percentage points of weight loss versus semaglutide alone might reduce her ApoB by an additional 5-8 mg/dL through weight-mediated mechanisms 2 / Theoretical . Whether that additional reduction is the most efficient intervention compared to statin titration depends on her statin history. For Nadia, who was not on a statin, the answer was clear: start high-intensity statin therapy first. That is not a CagriSema question. It is a statin question that had been missed.

Blood Pressure

Phase 2 systolic blood pressure reduction of approximately 5-7 mmHg 4 / Promising . REDEFINE 1 topline suggests maintained blood pressure benefit. For a woman with stage 1 hypertension in perimenopause, this is clinically relevant, blood pressure rises in the perimenopausal transition from sympathetic activation and aldosterone upregulation, and weight loss-mediated blood pressure reduction addresses part of the pathophysiology 5 / Solid 01225-8).

The HFpEF Signal

The semaglutide component’s HFpEF signal from STEP-HFpEF is established 5 / Solid . CagriSema’s 22.7% versus semaglutide’s 15% weight loss may produce greater pericardial fat reduction and greater diastolic function improvement. But this is a mechanistic extrapolation at this time 2 / Theoretical . No CagriSema HFpEF trial exists.

What the Cardiac Story Does Not Show for Women

Safety: The Full Picture for Women

8a. Black-Box Warning Status

No FDA-approved label exists. The GLP-1 RA class thyroid C-cell tumor signal from the semaglutide component applies. Women with personal or family history of MTC or MEN 2 are excluded from REDEFINE trials.

8b. Women-Specific Safety Concerns

GI adverse events in perimenopausal women: The additive gastroparetic effect of cagrilintide plus semaglutide produces nausea in approximately 44% of participants (Phase 2). Perimenopausal women with baseline delayed gastric emptying or GI motility symptoms may be disproportionately affected. The combination of two gastroparetic mechanisms on top of an already-slowed gut represents a clinical concern that is not adequately characterized by Phase 2 data and is an important gap for Phase 3 to fill 3 / Early .

Bone density: Weight loss reduces bone mineral density through reduced mechanical loading. Semaglutide Phase 3 bone density data from STEP trials showed approximately 0.5-1.0% reduction in lumbar spine BMD at 68 weeks 4 / Promising . The amylin receptor component of cagrilintide does not carry the glucagon receptor bone signal seen in retatrutide, but amylin has complex effects on bone: amylin receptors are expressed in osteoblasts and osteoclasts, and amylin has been shown to have anabolic effects on bone in some preclinical models 3 / Early . The net bone effect of CagriSema in postmenopausal women is unknown and warrants DXA monitoring.

Lean-mass loss: Expected to be similar to semaglutide alone (25-35% of weight lost as lean tissue without resistance training). The resistance training mandate applies to CagriSema as to all GLP-1 class drugs. For a 52-year-old woman losing 60 pounds on CagriSema, having 15-20 of those pounds be lean tissue represents a clinically significant sarcopenia risk.

Heart rate: Resting heart rate increase approximately 7-9 bpm in Phase 2. Women with baseline SVT, palpitations, or thyroid-mediated tachycardia should have cardiac evaluation before starting.

GI bleeding risk in patients on NSAIDs: Gastroparesis from dual-mechanism slowing may increase the time NSAIDs remain in gastric contact with the gastric mucosa, potentially increasing GI bleeding risk. Women who use NSAIDs chronically for perimenopausal joint pain or dysmenorrhea should discuss this interaction with their prescriber 3 / Early .

8c. Who Should Not Take This Medication

Based on expected label from semaglutide component and Phase 2 exclusion criteria:

• Personal or family history of MTC or MEN 2
• Active or recent pancreatitis
• Severe kidney disease
• History of significant gastroparesis or GI dysmotility
• Active or recent major cardiovascular event (within 60 days)
• Pregnancy or breastfeeding
• Active restrictive eating disorder

the clinical perspective for women: The right CagriSema patient is a woman with established metabolic cardiac risk, not a woman seeking cosmetic weight loss without cardiovascular or metabolic indication. The GI burden of two gastroparetic mechanisms, the unknown bone density profile, and the absence of CVOT data mean that for a woman without meaningful cardiovascular or metabolic risk, the risk-benefit calculation does not clearly favor CagriSema over established approved alternatives or lifestyle intervention.

8d. The Compounding Problem

Same as all pipeline drugs: CagriSema is not approved and cannot be legally compounded. Cagrilintide obtained outside of a Novo Nordisk-sponsored clinical trial is an unverified substance. The FDA has issued warning letters against unapproved peptide compounds broadly.

Clinical Decision-Making: This Medication for Women

The CagriSema Phenotype in Women

The women protocol for evaluating CagriSema candidacy begins with these clinical questions:

1. Has the patient responded to GLP-1 RA monotherapy with a plateau? If a woman has been on semaglutide 2.4 mg for 6+ months, lost significant weight, and plateaued, she is the canonical CagriSema patient from a mechanistic standpoint. The amylin mechanism addresses a different satiety circuit that has not yet been engaged.

2. Is postprandial hyperglycemia a component of her metabolic picture? The amylin mechanism specifically suppresses postprandial glucagon and glucose excursions. For a woman with prediabetes or T2D whose postprandial glucose is poorly controlled despite GLP-1 RA therapy, the amylin component of CagriSema addresses a specific gap.

3. Does she have baseline GI motility concerns? If yes, the combination of two gastroparetic agents is a clinical concern that may make CagriSema inappropriate regardless of the efficacy signal.

4. What is her menopausal status and bone density? DXA before starting is prudent for peri/postmenopausal women given the unknown bone signal from cagrilintide plus the weight-loss-mediated bone loading reduction.

5. What is her resting heart rate? Above 85 bpm warrants pre-prescribing cardiac evaluation.

The Five-Number Framework

ApoB: CagriSema may reduce ApoB by an additional 5-8 mg/dL beyond semaglutide alone through incremental weight loss. If ApoB is above 100 mg/dL, statin therapy should be initiated or improved first. CagriSema and statin are additive, not alternatives.

Lp(a): Weight loss does not meaningfully reduce Lp(a). If a woman’s ApoB is high partly because of raised Lp(a), CagriSema will not fix that. This is a genetic risk factor requiring specific counseling.

Fasting insulin: The amylin mechanism reduces insulin demand by suppressing postprandial glucose and slowing gastric emptying. For a woman with raised fasting insulin (above 12 uIU/mL), the amylin mechanism has specific mechanistic relevance.

CAC: For women with CAC > 0, the urgency of addressing ApoB and blood pressure with established therapies does not wait for CagriSema. The combination of CagriSema-mediated weight loss plus statin plus antihypertensive therapy is the framework if CagriSema becomes available.

Bone density (DXA): Replacing VO2max as the fifth metric for women on CagriSema: baseline DXA T-score is a critical safety metric given the potential bone signal and the established weight-loss-mediated bone loading reduction.

The Pre-Flight Checklist

Before starting CagriSema (when available):

• Full metabolic panel: ApoB, Lp(a), fasting insulin, lipid panel, HbA1c
• Thyroid function; calcitonin if MTC family history
• DXA if perimenopausal, postmenopausal, or BMI below 22
• Resting heart rate; ECG if arrhythmia history
• GI history: gastroparesis, motility disorders, chronic NSAID use
• Baseline weight, waist circumference, blood pressure
• Pregnancy status
• Current GLP-1 RA status and plateau assessment

The Monitoring Protocol

• Month 1: Weight, blood pressure, heart rate. GI symptom diary, early nausea, early satiety out of proportion to meal size, bloating. If gastroparesis-like symptoms, dose reassessment.
• Month 3: Metabolic panel: ApoB, HbA1c, fasting insulin. Blood pressure medication review. GI tolerability re-assessment.
• Month 6: Cardiac risk re-stratification. DXA if not done at baseline.
• Month 12: Full women panel. Decision point on long-term adherence plan.

What to Do Now

CagriSema is not available. Here is the action plan for women following this development:

Pipeline Note

CagriSema does not have FDA approval as of June 2026. All efficacy claims carry a Honesty Scale tag of Promising (Phase 3 topline, peer review pending) or Early (cardiovascular outcomes).

The Sex-Specific Publication Gap

The most important pipeline commitment Novo Nordisk can make for women is a sex-stratified publication of REDEFINE 1 data, including menopausal status subgroup, bone density in women, GI adverse events by hormonal status, and lean-mass preservation by sex. Whether this analysis will be included in the primary REDEFINE 1 publication is not known. If it is not included in the primary paper, it should be prioritized as a pre-specified sub-study publication.

What Women Are Actually Asking

Women in my clinic ask: “Is this safer than what I’m already taking?” and “Will it actually help my heart?” The honest answers: CagriSema adds GI adverse event burden versus semaglutide alone. The bone signal from the amylin component requires monitoring in postmenopausal women. The additional weight loss, if confirmed in women specifically, may provide meaningful incremental ApoB and blood pressure benefit. The cardiovascular outcome story has not been written yet for this drug in any population, let alone in women specifically.

A woman asking whether CagriSema is worth waiting for deserves a more nuanced answer than its manufacturer’s topline press release provides. The answer starts with knowing her five numbers and understanding how much of her cardiac risk is addressable by additional weight loss versus estrogen-withdrawal metabolic change versus genetic lipid burden.

References

1. Enebo LB, Berthelsen KK, Kaneko S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide 2.4 mg for weight management in adults with overweight and obesity: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286):1736-1748. DOI: 10.1016/S0140-6736(21)00845-X

2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. DOI: 10.1056/NEJMoa2307563

3. Kosiborod MN, Abildstrom SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069-1084. DOI: 10.1056/NEJMoa2305563

4. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183

5. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance. JAMA. 2021;325(14):1414-1425. DOI: 10.1001/jama.2021.3224

6. Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11(9):507-515. DOI: 10.1038/nrcardio.2014.83

7. Lutz TA. The role of amylin in the control of energy homeostasis. Am J Physiol Regul Integr Comp Physiol. 2010;298(6):R1475-1484. DOI: 10.1016/j.physbeh.2010.02.015

8. Heitkemper MM, Chang L. Do fluctuations in ovarian hormones affect gastrointestinal symptoms in women with irritable bowel syndrome? Gend Med. 2009;6(Suppl 2):152-167. DOI: 10.1053/j.gastro.2012.03.024

9. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death. Lancet. 2016;387(10022):957-967. DOI: 10.1016/S0140-6736(15)01225-8

10. Derby CA, Crawford SL, Pasternak RC, et al. Lipid changes during the menopause transition. Am J Epidemiol. 2009;169(11):1352-1361. DOI: 10.1097/gme.0b013e31816b4b74

11. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes. JAMA. 2013;310(13):1353-1368. DOI: 10.1001/jama.2013.278040

12. ClinicalTrials.gov NCT04842669: REDEFINE 1. Available at: https://clinicaltrials.gov/ct2/show/NCT04842669

13. American Heart Association. 2024 Statement on Emerging Antiobesity Medications and Cardiovascular Outcomes. (DOI pending final publication verification.)